EVH Earnings Prediction
The chart below shows how EVH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EVH sees a +1.93% change in stock price 10 days leading up to the earnings, and a +6.26% change 10 days following the report. On the earnings day itself, the stock moves by -0.13%. This data can give you a slight idea of what to expect for the next quarter's release.
EVH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
621.40M
21.60%
-3.98%
Gross Margin
8.21%
-54.41%
-30.95%
Operating Margin
-1.97%
-265.55%
-247.01%
Net Margin
-3.72%
-25.00%
-1588.00%
EPS
-0.27
-10.00%
350.00%
No Data Available
EVH Earnings Analysis
Evolent Health, Inc Class A Common Stock Corporation (EVH.N) Earnings Conference Call
Positive
Strong Q3 Earnings Performance: Earnings for Q3 2024 were announced, with adjusted EBITDA of $31.8 million, reflecting a strong performance despite higher than expected medical costs.
Record New Revenue Agreements: The company signed six new revenue agreements in Q3, marking the largest number of new revenue agreements announced in a single quarter since founding.
New Revenue Agreements Growth: The total number of new revenue agreements for the year reached 17, indicating robust growth and market demand for Evolent's services.
Top ACO Market Position: Evolent's ACO ranked as the 12th largest by total spend, placing it in the top 3% of all ACOs, showcasing its strong market position.
Strong Cash Flow Generation: Cash from operations was $18.7 million in the quarter, contributing to a year-to-date total of $67.2 million, indicating strong cash flow generation.
Negative
Earnings Miss Due to Costs: The third quarter 2024 earnings fell short of expectations for adjusted EBITDA, impacted by approximately $42 million in higher than expected medical costs.
EBITDA Decline Due to Costs: The adjusted EBITDA for Q3 2024 was $31.8 million, significantly lower than anticipated due to rising oncology costs.
Net Expenses Increase: The company experienced a $24 million increase in net expenses related to higher claims data processed from September through early November.
Medical Cost Inflation Factors: Medical costs inflation in Q3 2024 was driven by significant increases in disease prevalence and provider coding intensity, leading to higher expenses.
Revised EBITDA Outlook: The revised outlook for 2024 estimates adjusted EBITDA between $160 million and $175 million, reflecting a decline from previous expectations.
EVH FAQs
How does EVH typically perform around its earnings report dates?
Is Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EVH Earning Call Sentiment
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EVH.N
4.03%Positive
The earnings call highlights challenges such as increased medical expenses, cash flow issues, and reliance on credit facilities. Negative sentiments are reinforced by unclear management responses during the Q&A, especially regarding rate adjustments and accounts receivable dynamics. Despite new partnerships, the financial performance, including missed EBITDA expectations and revised revenue outlooks, suggests a negative short-term impact on the stock price. The market cap indicates a moderate reaction, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.
